secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-104574
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia Q2 net loss narrows to $101.3M; Phase 3 enrollment ahead; CMO to retire in 2026
--------------------------------------------------------------------------------

- Net loss $101.3M in Q2 2025 vs $147.0M a year ago; collaboration revenue $14.2M (up from $6.9M).
- Cash, equivalents and marketable securities $630.5M as of June 30, expected to fund ops into H1 2027.
- Phase 3 MAGNITUDE (ATTR-CM) enrollment ahead; study expanded from 765 to ~1,200 patients.
- Phase 3 HAELO (HAE) randomization expected to complete in Q3 2025; BLA submission targeted H2 2026.
- CMO Dr. David Lebwohl to retire effective Aug 7, 2026; will continue in role until successor appointed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000095017025104574/0000950170-25-104574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000095017025104574/ntla-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer